The effect of synbiotic on inflammatory markers and clinical manifestations in patients with C0VID-19
Phase 2
Recruiting
- Conditions
- Coronavirus infection.Coronavirus infection, unspecifiedB34.2
- Registration Number
- IRCT20200923048815N1
- Lead Sponsor
- Esfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Age 18-70 years old
Basic literacy
Writing ability and healthy memory
Mental conditions for continuing to attend the study and completing the consent form
Exclusion Criteria
Simultaneous participation in other clinical trial studies
Having other acute and serious diseases
Regular and periodic consumption of special dietary supplements or special diets
Taking other probiotic supplements
Receive corticosteroids in full dose
People with pancreatitis, sepsis, dialysis, central venous and chronic diarrhea
People waiting for abdominal surgery
People with acute immune deficiencies such as AIDS
People with short bowel syndrome or are at risk for mesenteric ischemia
Pregnant women and mothers who are breastfeeding.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Inflammatory markers. Timepoint: Before and 8 weeks after start of intervention. Method of measurement: Biochemical analysis.
- Secondary Outcome Measures
Name Time Method Clinical symptoms. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: Comment by physician.